CGT Catapult appoints Chief Business Officer

Jeanette Evans has joined the Cell and Gene Therapy Catapult as Chief Business Officer (CBO), taking over from Sharon Brownlow. Jeanette is a senior business development executive with over 25 years' experience in the pharmaceutical industry including working for leading companies such as AstraZeneca and Merck.

Formerly Vice President Business Development with Adaptimmune, through collaborations and partnerships with industry and academia her team supported the advancement of Adaptimmune’s cell therapies for the treatment of patients with solid tumours.  

In her role as CBO Jeanette will be responsible for leading the CGT Catapult’s business development and legal teams, providing support as they work to establish and maintain collaborations with academics and industry.

Matthew Durdy, Chief Executive of the CGT Catapult, commented: “Jeanette’s extensive experience in business development and excellent track record in global transactions will be a welcome addition to our leadership team.

"We look forward to working with Jeanette as we continue to strengthen our partnerships and support for the advanced therapies sector.

"I would also like to thank Sharon Brownlow for all her work over these past few years, she has been vital to the growth and development of our work in the UK, and we wish her all the best for the future.”

More information online